Sectoral Asset Management
Montréal, Québec
Investment Thesis
Sectoral's NEMO venture strategy targets late-stage emerging life science companies developing innovative medical treatments and medical technology devices based on disruptive technologies, with global sourcing across North America and Europe. The fund leverages extensive public market expertise to facilitate exits through IPOs and M&A transactions, focusing on companies with high-velocity characteristics demonstrating significant value creation potential.
Focus Areas
Investment Stage
Series B+
Sectors
Investment Signals
Check SizeC$6M to C$13M
GeographyGlobal
ProvincesQC
RoleLead
Revenue Stagetraction required
Business Modelsdeep-tech, IP-licensing
Sample Portfolio Companies
AMOLYT (acquired by AstraZeneca for $1B - 3.3x)
LENZ (IPO)
MINERALIS (IPO)
Ceribell
Heartflow
Management Team
9
9 professionals, 5 partners, 3 principals with scientific, financial and company expertise
What Makes Us Unique
Global sourcing with investment personnel in North America and Europe. Extensive public side experience enabling IPOs and M&A transactions.
AUM & Sources
Est. US$392M
Assets under management (estimated)
Sources
No public sources found.
Raising from Canadian VCs?Get AI-matched to your top investors in seconds.
Find My Investors →Similar Funds
See incorrect information?
Help us keep this directory accurate and up to date.